Novo Nordisk A/S Prix / Ventes
Quel est le Prix / Ventes de Novo Nordisk A/S?
Le Prix / Ventes de Novo Nordisk A/S est 13.34
Quelle est la définition de Prix / Ventes?
Le rapport prix / ventes est le prix des actions d'une entreprise par rapport à ses revenus.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Prix / Ventes des entreprises dans Miscellaneous secteur sur LSE par rapport à Novo Nordisk A/S
Que fait Novo Nordisk A/S?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Entreprises avec prix / ventes similaire à Novo Nordisk A/S
- Futu Ltd a Prix / Ventes de 13.30
- Tianfeng Securities Co a Prix / Ventes de 13.30
- SpringWorks Therapeutics a Prix / Ventes de 13.31
- Kronos Bio a Prix / Ventes de 13.33
- Bogota Corp a Prix / Ventes de 13.33
- Azelio AB (publ) a Prix / Ventes de 13.34
- Novo Nordisk A/S a Prix / Ventes de 13.34
- 333D a Prix / Ventes de 13.34
- CK Infrastructure a Prix / Ventes de 13.35
- Bombardier a Prix / Ventes de 13.36
- First Trust-abrdn Emerging Opportunity Fund a Prix / Ventes de 13.37
- BlackRock MuniYield Quality Fund III Inc a Prix / Ventes de 13.37
- Softimat S.A a Prix / Ventes de 13.37